Chemomab Therapeutics Ltd

Research Chemomab Therapeutics Ltd (CMMB) on Bullrun: market cap USD 11.66M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCMMB
• ExchangeNASDAQ
• CountryIsrael
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 11.66M
• Financial periodFY2025
• Net income-USD 9.00M
• Free cash flow-USD 11.13M

Valuation Snapshot

latest market cap is USD 11.66M.

About Chemomab Therapeutics Ltd

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.

Frequently asked questions

What is Chemomab Therapeutics Ltd's market cap?

Chemomab Therapeutics Ltd's market capitalization is USD 11.66M.

What does Chemomab Therapeutics Ltd do?

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases.